Lowering eye pressure in pigmentary glaucoma with DSLT
Official title: Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients
Run by Mann Eye Institute · NCT07281391 · Data updated 2026-11-12
This study will try Voyager DSLT to lower eye pressure in adults with pigmentary dispersion syndrome or mild-to-moderate pigmentary glaucoma.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Mann Eye Institute Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | March 19, 2026 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | April 9, 2026 |
| Trial ID | NCT07281391 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with pigmentary dispersion syndrome or mild-to-moderate pigmentary glaucoma who are treatment-naive or can undergo medication washout, with IOP 18–34 mmHg and central corneal thickness 480–600 µm, are the intended participants.
✕Probably not a fit
Patients with prior incisional glaucoma surgery, recent laser trabeculoplasty, other secondary glaucomas, significant ocular inflammation/infection, or those planning cataract surgery during follow-up are unlikely to be eligible or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-site, single-arm, prospective observational study of Voyager DSLT with follow-up visits up to 12 months. Eligible adults will be treatment-naive or undergo medication washout and receive DSLT in the study eye, with scheduled monitoring of intraocular pressure and glaucoma medication use. Clinical evaluations include IOP measurement and counting glaucoma medications at each visit to document post-procedure changes. Eyes with prior incisional glaucoma surgery, recent laser trabeculoplasty, other secondary glaucomas, or anticipated cataract surgery during follow-up are excluded.
Why it matters
Potential benefit: If successful, DSLT could lower intraocular pressure and reduce the need for glaucoma medications in patients with pigmentary glaucoma.
How similar studies have gone: Conventional selective laser trabeculoplasty (SLT) has proven IOP-lowering effects in open-angle glaucomas, but DSLT is a newer modality with limited specific data in pigmentary glaucoma.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss. * Treatment naive, or washed out IOP ranging from ≥18-34 mmHg * Central corneal thickness (CCT) 480-600 µm * Able to complete medication washout and follow-up Exclusion Criteria: * Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye * Prior laser trabeculoplasty \<3 years * Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years * Patients anticipating cataract surgery within the follow-up period * History of ocular inflammation and infection * All other secondary glaucoma including exfoliative * Patients unable to have DSLT treatment
Where it's running
-
Mann Eye Institute
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Alex Hacopian, MD — Mann Eye Institute
- Study coordinator: Melissa Wright
- Email: Melissa.Wright@manneye.com
- Phone: 713-580-2500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing XEN Glaucoma Gel Stent and Trabeculectomy for Glaucoma Treatment
This study is testing whether a new minimally invasive glaucoma implant works better than traditional surgery for improving vision in people with open angle glaucoma.
-
Electrical stimulation treatment for visual field defects in glaucoma patients
This study is testing if a new electrical stimulation treatment can help people with glaucoma keep their vision from getting worse while they continue using their regular eye drops.
-
Pigmentary glaucoma: does a 120° ab-interno trabeculotomy help
This study will see if performing an ab-interno 120° trabeculotomy can lower eye pressure and reduce medication needs in people with pigmentary glaucoma over six months.
-
Patient quality of life after different glaucoma surgeries
This project uses the NEI-VFQ-25 vision questionnaire to see if adults who have PreserFlo MicroShunt, trabeculectomy, or non-penetrating deep sclerectomy report different quality of life after surgery.
-
iStent infinite plus iDose TR for moderate-to-severe open-angle glaucoma
This trial will see if placing an iStent infinite device together with an iDose TR travoprost implant can lower eye pressure and reduce glaucoma eye drops for people with moderate to severe open-angle glaucoma not controlled by medication or laser.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.